PAD 135 (Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg)

Pill imprint PAD 135 has been identified as Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg.

Hydrochlorothiazide/moexipril is used in the treatment of high blood pressure and belongs to the drug class ACE inhibitors with thiazides. There is positive evidence of human fetal risk during pregnancy. Hydrochlorothiazide/moexipril 25 mg / 15 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for PAD 135

Hydrochlorothiazide and moexipril hydrochloride 25 mg / 15 mg PAD 135
Hydrochlorothiazide and moexipril hydrochloride
Imprint:
PAD 135
Strength:
25 mg / 15 mg
Color:
Yellow
Size:
14.00 mm
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
ACE inhibitors with thiazides
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Paddock Laboratories, Inc.
National Drug Code (NDC):
00574-0135
Inactive Ingredients:
lactose
magnesium oxide
crospovidone
magnesium stearate
povidone
silicon dioxide
hypromelloses
titanium dioxide
polyethylene glycol 400
ferric oxide red

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web2)